Title:
EZH2 INHIBITOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2020/224607
Kind Code:
A1
Abstract:
The present application provides a compound represented by formula (I), or a pharmaceutically acceptable salt, ester, prodrug, complex, solvate, hydrate, or isomer thereof; and a use thereof in preparing drugs used to treat EZH2-mediated disease.
Inventors:
LI JIN (CN)
CHEN HONGDAO (CN)
LIU LIU (CN)
YANG MINMIN (CN)
CHEN HONGDAO (CN)
LIU LIU (CN)
YANG MINMIN (CN)
Application Number:
PCT/CN2020/088861
Publication Date:
November 12, 2020
Filing Date:
May 07, 2020
Export Citation:
Assignee:
PHARMABLOCK SCIENCES NANJING INC (CN)
International Classes:
A61K31/435; C07D401/14; A61P35/00; C07D401/06
Domestic Patent References:
| WO2019222272A1 | 2019-11-21 | |||
| WO2012118812A2 | 2012-09-07 | |||
| WO2015193768A1 | 2015-12-23 | |||
| WO2015077194A1 | 2015-05-28 |
Foreign References:
| CN107922434A | 2018-04-17 | |||
| CN105452246A | 2016-03-30 |
Other References:
AMANTULLAH ANSARI ET AL.: "Novel 3-methylindoline inhibitors of EZH2: Design, synthesis and SAR", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 27, no. 2, 25 November 2016 (2016-11-25), pages 217 - 222, XP029862595
QIN, YU ET AL.: "EZH2 inhibitors and antitumor therapy", CHEMISTRY OF LIFE, vol. 37, no. 3, 15 June 2017 (2017-06-15), pages 401 - 407, XP055752078
QIN, YU ET AL.: "EZH2 inhibitors and antitumor therapy", CHEMISTRY OF LIFE, vol. 37, no. 3, 15 June 2017 (2017-06-15), pages 401 - 407, XP055752078
Attorney, Agent or Firm:
BEYOND ATTORNEYS AT LAW (CN)
Download PDF:
Previous Patent: ENGINEERED IMMUNE CELL TARGETING BCMA AND USE THEREOF
Next Patent: METHOD AND APPARATUS FOR LOSS-AWARE OPTICAL ROUTING
Next Patent: METHOD AND APPARATUS FOR LOSS-AWARE OPTICAL ROUTING